Terms: = Uterine cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP
163 results:
1. Effects of brd4 inhibitor JQ1 on the expression profile of super-enhancer related lncRNAs and mRNAs in cervical cancer HeLa cells.
Zheng J; Huang B; Xiao L; Wu M
PeerJ; 2024; 12():e17035. PubMed ID: 38410799
[TBL] [Abstract] [Full Text] [Related]
2. Impact of HPV strains on molecular mechanisms of cervix cancer.
Sharma S; Chauhan D; Kumar S; Kumar R
Microb Pathog; 2024 Jan; 186():106465. PubMed ID: 38036109
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and feasibility of 3D printed redesigned Venezia™ applicator for treating advanced cervix and recurrent endometrial cancer.
Lee VWY; Yip WWL; Tang SYK; Leung MPH; Kwan KKK; Liu ACH; Chan VNY; Wu JWS; Cheng JNS; Chiang CL; Ho-Fun Lee V
Phys Med; 2023 Oct; 114():103150. PubMed ID: 37757501
[TBL] [Abstract] [Full Text] [Related]
4. HER-2 overexpression in female genital tract clear cell carcinomas: Evaluation of different scoring guidelines, clinicopathological features and prognostic impact.
Edjtemaei R; Nili F; Jahanzad I; Ameli F; Ghasemi D
Ann Diagn Pathol; 2023 Oct; 66():152184. PubMed ID: 37543027
[TBL] [Abstract] [Full Text] [Related]
5. Folate receptor alpha is widely expressed and a potential therapeutic target in uterine and ovarian carcinosarcoma.
Saito A; Nishikawa T; Yoshida H; Mizoguchi C; Kitadai R; Yamamoto K; Yazaki S; Kojima Y; Ishikawa M; Kato T; Yonemori K
Gynecol Oncol; 2023 Sep; 176():115-121. PubMed ID: 37506533
[TBL] [Abstract] [Full Text] [Related]
6. [Clinicopathological and gene mutation characteristics of uterine carcinosarcoma].
Tu J; Xu JZ; Zhang YS; Deng LF
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(24):1864-1867. PubMed ID: 37357193
[TBL] [Abstract] [Full Text] [Related]
7. Bethesda system reporting rates, histological follow-up and HPV genotypes distribution of abnormal cytology in Anhui province of China: Analysis of 93,168 cervical liquid-based cytology test reports.
Xu H; Chen Y; Zhao C; Wang Q; Tang M; Zhang W; Wang Q; Lou R; Liu T; Feng Y; Zhang H
Diagn Cytopathol; 2023 Aug; 51(8):501-510. PubMed ID: 37114437
[TBL] [Abstract] [Full Text] [Related]
8. Gynecological cancer prognosis using machine learning techniques: A systematic review of the last three decades (1990-2022).
Sheehy J; Rutledge H; Acharya UR; Loh HW; Gururajan R; Tao X; Zhou X; Li Y; Gurney T; Kondalsamy-Chennakesavan S
Artif Intell Med; 2023 May; 139():102536. PubMed ID: 37100507
[TBL] [Abstract] [Full Text] [Related]
9. Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma.
Sukov WR; Zhou J; Geiersbach KB; Keeney GL; Carter JM; Schoolmeester JK
Hum Pathol; 2023 Jul; 137():94-101. PubMed ID: 37094656
[TBL] [Abstract] [Full Text] [Related]
10. Navigating Practice Issues Related to the Unsatisfactory Cervicovaginal Papanicolaou Test: Survey Results of Laboratories Participating in the 2020 College of American Pathologists PAP Education Program.
Goyal A; Booth CN; Souers RJ; Tabbara SO; Roberson J; Henry MR; Sundling KE; Goodrich K; Nguyen L
Arch Pathol Lab Med; 2024 Jan; 148(1):48-54. PubMed ID: 37074866
[TBL] [Abstract] [Full Text] [Related]
11. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis.
Bruce SF; Wu S; Ribeiro JR; Farrell A; Oberley MJ; Winer I; Erickson BK; Klc T; Jones NL; Thaker PH; Powell MA
Gynecol Oncol; 2023 May; 172():98-105. PubMed ID: 37003074
[TBL] [Abstract] [Full Text] [Related]
12. HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy.
Joehlin-Price AS; Komforti MK; Ladwig NR; Devine P; Hoyle C; McCoy L; Sprague C; Astbury C; Hoda R; Chen YY; Garg K
Am J Surg Pathol; 2023 May; 47(5):580-588. PubMed ID: 36939053
[TBL] [Abstract] [Full Text] [Related]
13. Current Laboratory Testing Practices for Assessment of ERBB2/HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma.
Hagemann IS; Bridge JA; Tafe LJ; Hameed MR; Moncur JT; Bellizzi AM; Dolan M; Vasalos P; Kane ME; Souers RJ; Yemelyanova A
Arch Pathol Lab Med; 2023 Oct; 147(10):1148-1157. PubMed ID: 36538387
[TBL] [Abstract] [Full Text] [Related]
14. The statuses of HER2 expression and mismatch repair in endometrial clear cell carcinoma.
Bayramoglu Z; Erozbek SY; Ozdemir IA; Ulker V; Muezzinoglu B
Pathol Res Pract; 2023 Jan; 241():154258. PubMed ID: 36516643
[TBL] [Abstract] [Full Text] [Related]
15. Deregulation of SPOP in cancer.
Zhang H; Jin X; Huang H
Cancer Res; 2023 Feb; 83(4):489-499. PubMed ID: 36512624
[TBL] [Abstract] [Full Text] [Related]
16. HER2 in uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
Klc TR; Wu S; Wilhite AM; Jones NL; Powell MA; Olawaiye A; Girda E; Brown J; Puechl A; Ali-Fehmi R; Winer IS; Herzog TJ; Korn WM; Erickson BK
Gynecol Oncol; 2022 Nov; 167(2):289-294. PubMed ID: 36114027
[TBL] [Abstract] [Full Text] [Related]
17. The brd4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer.
Pang Y; Bai G; Zhao J; Wei X; Li R; Li J; Hu S; Peng L; Liu P; Mao H
J Transl Med; 2022 Jul; 20(1):336. PubMed ID: 35902869
[TBL] [Abstract] [Full Text] [Related]
18. Biomarker characterization in endometrial cancer in Italy: first survey data analysis.
Zannoni GF; Santoro A; D'Alessandris N; Scaglione G; Inzani F; Angelico G; Bragantini E; Piermattei A; Cianfrini F; Bisaro B; Fassan M;
Pathologica; 2022 Jun; 114(3):189-198. PubMed ID: 35775705
[TBL] [Abstract] [Full Text] [Related]
19. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.
Buza N; Hui P
Arch Pathol Lab Med; 2022 Jun; 146(5):0. PubMed ID: 35687792
[TBL] [Abstract] [Full Text] [Related]
20. Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma.
Saglam O; Cao B; Wang X; Toruner GA; Conejo-Garcia JR
PLoS One; 2022; 17(2):e0264014. PubMed ID: 35226658
[TBL] [Abstract] [Full Text] [Related]
[Next]
